CN111789902A - Application of content in Yunweining capsule in preparing anti-helicobacter pylori medicine - Google Patents

Application of content in Yunweining capsule in preparing anti-helicobacter pylori medicine Download PDF

Info

Publication number
CN111789902A
CN111789902A CN202010907128.1A CN202010907128A CN111789902A CN 111789902 A CN111789902 A CN 111789902A CN 202010907128 A CN202010907128 A CN 202010907128A CN 111789902 A CN111789902 A CN 111789902A
Authority
CN
China
Prior art keywords
helicobacter pylori
stramonium
leaves
capsule
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010907128.1A
Other languages
Chinese (zh)
Inventor
朱明浩
沈志强
陈锡强
白丽梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010907128.1A priority Critical patent/CN111789902A/en
Publication of CN111789902A publication Critical patent/CN111789902A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to an application of contents in Yunwening capsules in preparing an anti-helicobacter pylori medicament, and belongs to the technical field of traditional Chinese medicines. The invention discloses an application of contents in Yunwening capsules in preparing anti-helicobacter pylori medicaments. The medicament for resisting the helicobacter pylori is prepared by taking the steamed stramonium leaves and the fried bergenia crassifolia as active ingredients in equal mass ratio, and the micro-aerobic culture method is used for observing the influence on the growth of the helicobacter pylori, so that the medicament is found to have the effect of inhibiting the helicobacter pylori. The invention solves the adverse consequences caused by the prior use of a large amount of antibiotics, and is easy to popularize and apply.

Description

Application of content in Yunweining capsule in preparing anti-helicobacter pylori medicine
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of contents in Yunwening capsules in preparation of an anti-helicobacter pylori medicine.
Background
Peptic Ulcer (PU) is a digestive disease with high incidence and recurrence rate worldwide. It occurs primarily in the stomach and duodenum, with duodenal ulcers being more common. PU can be caused by the strengthening of the action of attacking factors or the weakening of the action of defense factors in the digestive system, wherein the main attacking factors comprise helicobacter pylori infection, hypersecretion of gastric acid, ethanol, certain medicines and the like.
Helicobacter pylori (Helicobacter PyloriHp) infection has been confirmed to be an important cause of PU formation. The detection rate of Hp of PU patients is obviously higher than that of normal people, and the recurrence rate of ulcer patients after Hp eradication is obviously reduced. The main mechanism comprises: the toxins of Hp cause gastric mucosal damage, Hp infection causes abnormal gastric acid secretion, and the immune response of the host mediates gastric mucosal damage. Therefore, eradication of Hp has become an effective means for treating PU and preventing relapse in modern medicine.
Currently, the drugs such as clarithromycin, amoxicillin and the like are commonly used in clinic as anti-Hp drugs for treating PU. The antibiotic has antibacterial effect. However, these drugs are not acid resistant, so that a single drug has poor Hp-resistant therapeutic effect, and most clinically, antibiotics and Proton Pumps (PPI) and other acid inhibitors are combined for application. Including dual, triple and quadruple therapies, with triple therapy (i.e., PPI-based, two antibiotic combinations) being the most widely used. As with the standard triple treatment protocol: omeprazole + amoxicillin + clarithromycin. The use of antibiotics in large quantities also causes problems. Certainly, there are also methods for treating PU by combining traditional Chinese medicine with western medicine and methods for treating PU by traditional Chinese medicine, and people are always searching for new medicines to make up for the existing deficiencies.
The prescription of Yunweining capsule is made from folk prescription, and in the course of formation a patent is also applied, its patent number is ZL200510048693.2 "A medicine for curing gastropathy and gastric ulcer and its preparation method", said patent is owned by my company. In the subsequent research, the prescription and the preparation method are optimized, and the prescription and the preparation method are used as national medicine declaration, and the national medicine standard character Z20026811 is obtained. Has already been put into production and marketed, is widely used in clinic, and has definite curative effect, safe use and stable quality.
In order to further and deeply clarify the function, indication and action mechanism of the Yunweisuning capsule, research on the action and mechanism of the Yunweisuning capsule for treating experimental gastric ulcer is carried out, wherein the Yunweisuning capsule is found to have the effect of eradicating Hp, and has positive significance for treating PU. The Yunweising capsule has the function of eradicating Hp, and is not reported at present.
Disclosure of Invention
The invention aims to solve the defects of the prior art and provides the application of the content in the Yunwening capsule in preparing the anti-helicobacter pylori medicament.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the content of the Yunweining capsule is used for preparing the anti-helicobacter pylori medicine.
Further, preferably, the content of the yunweining capsule comprises datura stramonium leaf and bergenia cordifolia.
Further, it is preferable that the anti-helicobacter pylori drug is prepared by using the steamed stramonium leaves and the fried bergenia purpurascens as active ingredients in equal mass ratio.
Further, preferably, the pharmaceutical dosage form includes tablets, granules, oral liquids, powders and capsules.
The invention also provides an anti-helicobacter pylori medicament, and the active ingredients of the anti-helicobacter pylori medicament comprise the steamed stramonium leaves and the fried bergenia purpurascens in equal mass ratio.
Further, preferably, the preparation method of the steamed stramonium leaves comprises the following steps: picking up stramonium leaves, steaming the stramonium leaves in steaming equipment, controlling the temperature to be 70-100 ℃, continuously heating for 20-40 minutes, taking out the steamed stramonium leaves, and drying the stramonium leaves at 40-75 ℃.
Yunweining capsule is prepared from folium Daturae (processed) 100g and rhizoma Seu herba Bergeniae (parched) 100 g. Pulverizing the above two materials into fine powder, mixing, and making into capsule 1000 granules. The Yunwening capsule implements the national drug Standard WS-11176 (ZD-1176) -2002-2012Z issued by the State food and drug administration. The YUNWEINING Capsule has effects of warming spleen and stomach, dispelling cold, relieving spasm and relieving pain. The traditional Chinese medicine composition is used for treating gastric and duodenal ulcers caused by congealing cold and blood stasis, chronic gastritis and epigastric pain caused by gastrospasm in the functions and main treatment, but spasmolysis and pain relief are only one of macroscopic indexes.
The invention respectively adopts indomethacin, ethanol and acetic acid to replicate a rat gastric ulcer model, and perfusing 50, 100 and 200mg/kg of Yunwening capsule contents after the model is replicated, namely: detecting the influence of the composition of the steamed stramonium leaves and the fried bergenia crassifolia on the ulcer area; meanwhile, HE staining observed pathological changes of gastric mucosa; detecting the amount and total acidity of the stomach fluid, and measuring the concentrations of pepsin and gastrin by adopting an ELISA method; detecting the concentrations of phospholipid and hexosamine as main hydrophobic components of gastric mucosa with ultraviolet spectrophotometer; respectively adopting immunohistochemistry and RT-qPCR methods to detect the expressions of gastric mucosal epidermal growth factor (EGT), tumor necrosis factor alpha (TNF-alpha), interleukin (IL-8) and prostaglandin E2 (PGE 2) protein and mRNA thereof; microaerophilic culture was observed for effects on the growth of H.pylori.
Thus, it was confirmed that:
a. the yunweining capsule has therapeutic effect on gastric ulcer of rat induced by indometacin, ethanol and acetic acid.
b. The YUNWEINING Capsule can improve gastric mucosa hydrophobicity, protect gastric mucosa barrier, and enhance gastric mucosa defense function.
c. The Yunweining capsule can reduce the level of pepsin and gastrin, reduce the acidity of gastric acid and is favorable for repairing damaged gastric mucosa.
d. Increasing the expression of epidermal growth factor (EGT) and prostaglandin E2 (PGE 2), and decreasing the expression of tumor necrosis factor alpha (TNF-alpha) and interleukin (IL-8) may be one of the mechanisms of action.
e. The Yunweining capsule has the effect of inhibiting helicobacter pylori in vitro.
Compared with the prior art, the invention has the beneficial effects that:
the invention discloses an application of contents in Yunwening capsules in preparing anti-helicobacter pylori medicaments. The medicament for resisting helicobacter pylori is prepared by taking the steamed stramonium leaves and the fried bergenia crassifolia as active ingredients in equal mass ratio, has an inhibiting effect on helicobacter pylori in vitro, and clinical tests show that the medicament is effective on Hp, so that adverse consequences caused by the existing mass use of antibiotics are solved; the method comprises the following specific steps:
1. warming the middle energizer to dispel cold, and relieving spasm and pain; further, it is effective against gastric ulcer; further, it is effective against helicobacter pylori; can treat both symptoms and root causes, and the Yunwening capsule becomes a more comprehensive medicine for treating gastric ulcer (PU).
2. The prescription is unique. It comes from Yi nationality and is preferred.
3. The medicinal part is unique. The mandragora leaves are rarely used and are unique across the country.
4. The preparation method is unique. Steaming folium Daturae Metelis, parching rhizoma Seu herba Bergeniae, reducing toxicity, and enhancing effects.
5. The quality is controllable, safe and effective. The detection items in the preparation standard cover all medicinal flavors in the prescription, and the content is measured and controlled by HPLC method, and each granule contains 0.12-0.18mg of Datura stramonium leaf calculated by atropine sulfate.
Detailed Description
The present invention will be described in further detail with reference to examples.
It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples do not specify particular techniques or conditions, and are performed according to the techniques or conditions described in the literature in the art or according to the product specifications. The materials or equipment used are not indicated by manufacturers, and all are conventional products available by purchase.
The percentage numbers are percentages by mass unless otherwise indicated.
Example 1
The content of the Yunweining capsule is used for preparing the anti-helicobacter pylori medicine.
Preferably, the content of YUNWEINING Capsule comprises folium Daturae and rhizoma Seu herba Bergeniae.
More preferably, the medicament for resisting helicobacter pylori is prepared by adopting steamed stramonium leaves and fried bergenia crassifolia as active ingredients in equal mass ratio.
It will be appreciated by those skilled in the art that the pharmaceutical dosage forms include tablets, granules, oral liquids, powders and capsules.
Example 2
An anti-helicobacter pylori medicine contains, as active ingredients, steamed stramonium leaf and parched bergenia purpurascens.
The preparation method of the steamed stramonium leaves comprises the following steps: picking up stramonium leaves, steaming the stramonium leaves in steaming equipment, controlling the temperature to be in a range of 70-80 ℃, continuously heating for 40 minutes, taking out the steamed stramonium leaves, and drying the stramonium leaves at 40 ℃.
Example 3
An anti-helicobacter pylori medicine contains, as active ingredients, steamed stramonium leaf and parched bergenia purpurascens.
The preparation method of the steamed stramonium leaves comprises the following steps: picking up stramonium leaves, steaming the stramonium leaves in steaming equipment, controlling the temperature to be within 90-100 ℃, continuously heating for 20 minutes, taking out the steamed stramonium leaves, and drying the stramonium leaves at 75 ℃.
Example 4
An anti-helicobacter pylori medicine contains, as active ingredients, steamed stramonium leaf and parched bergenia purpurascens.
The preparation method of the steamed stramonium leaves comprises the following steps: picking up stramonium leaves, steaming the stramonium leaves in steaming equipment, controlling the temperature to be within the range of 75-95 ℃, continuously heating for 30 minutes, taking out the steamed stramonium leaves, and drying the stramonium leaves at 55 ℃.
EXAMPLE 5 Effect of in vitro micro-aerobically cultured helicobacter pylori
1. Test strains
Helicobacter pylori standard strain (Hp), ATCC43504 was purchased from the Guangdong province culture collection.
2. Strain resuscitation
(1) Taking ATCC43504 strain frozen in-80 deg.C refrigerator, and thawing at 4 deg.C;
(2) after the strain is completely melted, centrifuging at 8000rpm for 2 mim;
(3) the strain is settled at the bottom of the tube, the supernatant is discarded, and 80 mul of liquid is reserved at the bottom of the tube;
(4) sucking 20 mul of bacterial suspension by using a sterile pipette and inoculating the bacterial suspension on a Columbia blood agar plate;
(5) uniformly smearing bacterial suspension on the whole flat plate by using sterile inoculating loop, and placing the flat plate in a sealed culture boxIn the middle, a micro-aerobic gas generating bag (5% O) is arranged2、10%CO2、80%N2、5%H2) And sterilized triple distilled water (10 ml) was cultured at 37 ℃ for 72 hours.
3. Bacterial strain cryopreservation
Liquid cultured bacterial cultures: taking 0.2ml of bacteria culture solution, adding 0.80ml of autoclaved skim milk, shaking the culture solution to uniformly distribute the skim milk, transferring the skim milk into a marked freezing tube, sealing, freezing with liquid nitrogen, and storing at-80 deg.C for a long time. At the time of recovery, the cryopreserved tubes were placed in an incubator at 37 ℃ overnight. The next day, the bacterial solution in the freezing tube was dipped with an inoculating loop on a clean bench, and after the plate was scratched on a Columbia blood agar plate, the plate was placed in a closed culture box, and a microaerophilic gas-producing bag and 10ml of sterile triple distilled water were placed therein, and cultured in an incubator at 37 ℃.
4. Preparation of bacterial suspension
Taking ATCC43504, coating on Columbia blood agar plate with inoculating loop, culturing at 37 deg.C in microaerophilic environment for 72 hr, observing colony morphology and characteristics, washing inoculated ATCC43504 with sterile 0.9% NaCl solution for 3 days to obtain 0.9% NaCl bacterial suspension, blank zeroing with PBS control group, and correcting suspension concentration to 1 × 10 according to 660nm optical density value (OD value) of ultraviolet spectrophotometer7CFU/ml。
5. Determination of minimum inhibitory concentration of Yunweising capsule
(1) Respectively dissolving 2g of yunweining capsule content and 25mg of omeprazole in 5ml of PBS, fully oscillating, uniformly mixing, filtering, and sterilizing for later use;
(2) taking 10 15ml centrifuge tubes, and operating in an ultra-clean bench;
(3) adding Columbia blood agar culture medium 3.2ml in the 1 st tube, and adding 2ml in each tube;
(4) adding 0.8ml of the Yunwening capsule liquid medicine treated in the step (1) into the 1 st tube, and uniformly mixing; then sucking 2ml from the 1 st tube, transferring to the 2 nd tube, and mixing uniformly; sucking 2ml from the 2 nd tube, moving to the 3 rd tube, and so on until the 9 th tube; treating omeprazole liquid medicine by the same method;
(5) sequentially adding 0.1ml to the 8 th tube and the 10 th tube of the bacterial suspension obtained in the step (4) into the test tube of the diluted medicine; only adding the Yunweining capsule or omeprazole liquid medicine treated in the step (1) in the 9 th tube as a negative control, and only adding the bacterial suspension obtained in the step (4) in the 10 th tube as a positive control;
(6) placing in a 37 ℃ incubator for microaerophilic culture for 20h, taking out and observing the growth condition of bacteria, and measuring an OD value at 660nm by using an ultraviolet spectrophotometer;
(7) minimum Inhibitory Concentration (MIC) of drug pair ATCC43504 was given as the minimum drug dilution tube for sterile growth. The inhibition effect of the Yunweining capsule on helicobacter pylori in vitro is evaluated.
The results show that MIC of Yunwening capsule and omeprazole are 40mg/ml and 0.125mg/ml respectively, and are shown in Table 1.
TABLE 1
Figure DEST_PATH_IMAGE002
The contents of the Yunwening capsule are as follows: the anti-helicobacter pylori medicine is prepared by adopting steamed datura stramonium leaf and fried bergenia cordifolia in equal mass ratio, preferably, the steamed datura stramonium leaf fine powder and the fried bergenia cordifolia fine powder are respectively 100g, and after being mixed uniformly, the mixture is filled into capsules to be prepared into 1000 capsules. When in use, the preparation is orally taken, 1-2 granules are recommended once, and 3 times a day are taken.
Example 6
And (3) clinical trials: the invention also makes clinical test, and part of the clinical test data is shown in table 2.
TABLE 2
Figure DEST_PATH_IMAGE004
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.

Claims (6)

1. The content of the Yunweining capsule is used for preparing the anti-helicobacter pylori medicine.
2. The use of the content of Yunwening capsule as the medicine for resisting helicobacter pylori according to claim 1, is characterized in that: the contents of YUNWEINING Capsule comprise folium Daturae and rhizoma Seu herba Bergeniae.
3. The use of the content of Yunwening capsule as claimed in claim 2 for preparing anti-helicobacter pylori medicine is characterized in that: adopts the steamed stramonium leaves and the fried bergenia crassifolia as active ingredients to prepare the anti-helicobacter pylori medicament.
4. The use of the content of Yunwening capsule as the medicine for resisting helicobacter pylori according to claim 1, is characterized in that: the medicament dosage forms comprise tablets, granules, oral liquid, powder and capsules.
5. The anti-helicobacter pylori drug is characterized in that the active ingredients of the anti-helicobacter pylori drug comprise steamed stramonium leaves and fried bergenia purpurascens.
6. The anti-helicobacter pylori drug according to claim 5, wherein the steamed stramonium leaves are prepared by a method comprising: picking up stramonium leaves, steaming the stramonium leaves in steaming equipment, controlling the temperature in the range of 70-100 ℃ during steaming, continuously heating for 20-40 minutes, taking out the steamed stramonium leaves, and drying the stramonium leaves at 40-75 ℃.
CN202010907128.1A 2020-09-02 2020-09-02 Application of content in Yunweining capsule in preparing anti-helicobacter pylori medicine Pending CN111789902A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010907128.1A CN111789902A (en) 2020-09-02 2020-09-02 Application of content in Yunweining capsule in preparing anti-helicobacter pylori medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010907128.1A CN111789902A (en) 2020-09-02 2020-09-02 Application of content in Yunweining capsule in preparing anti-helicobacter pylori medicine

Publications (1)

Publication Number Publication Date
CN111789902A true CN111789902A (en) 2020-10-20

Family

ID=72834166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010907128.1A Pending CN111789902A (en) 2020-09-02 2020-09-02 Application of content in Yunweining capsule in preparing anti-helicobacter pylori medicine

Country Status (1)

Country Link
CN (1) CN111789902A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1539492A (en) * 2003-10-27 2004-10-27 桐 王 Medication for treating astriv disease, gastric ulcer and preparation technique
CN1824023A (en) * 2005-12-15 2006-08-30 王桐 Medicine for treating gastropathy and gastrohelcosis and its preparation method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1539492A (en) * 2003-10-27 2004-10-27 桐 王 Medication for treating astriv disease, gastric ulcer and preparation technique
CN1824023A (en) * 2005-12-15 2006-08-30 王桐 Medicine for treating gastropathy and gastrohelcosis and its preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘方伶等: "左金溃疡组方对消化性溃疡的临床研究", 《中国临床医生杂志》 *

Similar Documents

Publication Publication Date Title
CN114317353B (en) Lactobacillus plantarum ZJFFYJ 7 and application thereof
CN115414391B (en) Application of lactobacillus plantarum MA2 in preparation of medicine for preventing or improving adenine-induced chronic kidney disease
CN102512380A (en) Freeze-dried powder injection with omeprazole sodium as active component and preparation method thereof
CN105617316A (en) Antibacterial disinfectant for clinical laboratory and preparation method
CN111729076B (en) Application of recombinant human lysozyme
CN111789902A (en) Application of content in Yunweining capsule in preparing anti-helicobacter pylori medicine
CN105709081A (en) Pharmaceutical composition used for treating infectious rhinitis of chicken, applications thereof, and feed
CN116172997B (en) Application of phenyllactic acid in inhibiting helicobacter pylori infection
CN113413402B (en) Application of plum blossom extract in preparation of medicine for treating helicobacter pylori infection disease
CN105125507B (en) A kind of Esomeprazole sodium injection freezes compound powder and preparation method thereof
LU101523B1 (en) Application of taraxasterone in a preparation of medicament for preventing and treating senile dementia
WO2017020861A1 (en) Application of polygonum capitatum composition in resisting helicobacter pylori
TWI727176B (en) Use of pharmaceutical compositions in preparing pharmaceuticals for anti-helicobacter pylori
WO2020143332A1 (en) Application of ilexgenin o in preparation of medication for preventing and treating alzheimer's disease
CN107007826B (en) Active protein of isatis root and its preparing process and application
CN106924235A (en) Application of the usnic acid in antineoplastic sensitizer is prepared
CN107349376B (en) Anti-coccidiosis probiotic medicine and preparation method and application thereof
CN106924253A (en) Application of 8- the third dicyan jamaicins in antineoplastic sensitizer is prepared
CN108743633B (en) Application of combination of radix Actinidiae chinensis total triterpenes and radix Actinidiae chinensis polysaccharide in preparing medicine for preventing and treating digestive system tumor and lung cancer
CN109999086A (en) Treat pig polyserositis and arthritic Chinese medicine composition and preparation method thereof
CN115212247B (en) Preparation of nitraria tangutorum bobr and application thereof
CN108619273B (en) Preparation method of plant fruit core oral liquid for treating helicobacter pylori
RU2545687C1 (en) Method for helicobacter pylori eradication of gastroduodenal zone
CN115137774B (en) Application of lignum sappan leaf extract in preparing anti-candida krusei medicine
CN107929344B (en) Lithospermum compound composition for preventing and treating laryngeal cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201020